hrs4r
 I want to donate

WALTER HERNAN CARBAJAL OCHOA

Firma
WALTER HERNAN CARBAJAL-OCHOA
Position
Investigador/a Pre-doctoral – R1
Predoctoral Researchers – R1

Publicacions

Teixidor E, Sais E, Vásquez CA, Carbajal W, Hernández A, Sánchez G, Izquierdo A, Verdura S, Menéndez JA, Bosch-Barrera J

Addendum: Immune-related adverse events and atypical radiological response with checkpoint inhibitor immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma.

Oncotarget, 2023, 14, 668-668 dx.doi.org/10.18632/oncotarget.28471
Carbajal-Ochoa WH, Johnson D, Alvarez A, Bernal AM, Anampa JD

Racial disparities in treatment and outcomes between non-Hispanic Black and non-Hispanic White women with nonmetastatic inflammatory breast cancer.

BREAST CANCER RESEARCH AND TREATMENT, 2023, 201, 275-287 dx.doi.org/10.1007/s10549-023-07018-7
Carbajal-Ochoa W, Bravo-Solarte DC, Bernal AM, Anampa JD

Benefit of adjuvant chemotherapy in lymph node-negative, T1b and T1c triple-negative breast cancer.

BREAST CANCER RESEARCH AND TREATMENT, 2023, 203, 257-269 dx.doi.org/10.1007/s10549-023-07132-6
García-Velasco A, Zacarías-Pons L, Teixidor H, Valeros M, Liñan R, Carmona-Garcia MC, Puigdemont M, Carbajal W, Guardeño R, Malats N, Duell E, Marcos-Gragera R

Incidence and Survival Trends of Pancreatic Cancer in Girona: Impact of the Change in Patient Care in the Last 25 Years

INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2020, 17 dx.doi.org/10.3390/ijerph17249538
Garcia Velasco, A., Quintana, M., Puigdemont Guinart, M., Carbajal, W., Sanchez, R. Guardeno, Anna, V., Nica, A., Villavicencio, A., Vilardell, L., Marcos-Gragera, R.

Incidence and trends of biliary tract cancer in Girona: A population-based study from the Girona Cancer Registry (1994-2016)

ANNALS OF ONCOLOGY, 2020, 31, 160-161 dx.doi.org/10.1016/j.annonc.2020.04.298
Teixidor E, Sais E, Vásquez CA, Carbajal W, Hernández A, Sánchez G, Izquierdo A, Verdura S, Menéndez JA, Bosch-Barrera J

Immune-related adverse events and atypical radiological response with checkpoint inhibitor immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma.

Oncotarget, 2018, 9, 33043-33049 dx.doi.org/10.18632/oncotarget.25984

Formulari de contacte

About IDIBGI!

menu